AnPac Bio-Medical Science Co., Ltd.
ANPC · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.01 | -0.00 | 0.01 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -2.21 | -1.51 | -2.79 | -4.46 |
| Quality | ||||
| ROIC | -797.67% | -175.12% | -109.67% | -40.44% |
| Gross Margin | -7.55% | 78.01% | 70.60% | 55.39% |
| Cash Conversion Ratio | 1.13 | 58.67 | – | 0.49 |
| Growth | ||||
| Revenue 3-Year CAGR | -16.08% | 11.74% | 8.74% | 15.72% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.32 | -0.06 | -0.52 | -1.23 |
| Interest Coverage | -404.67 | -216.34 | -366.01 | -156.30 |
| Efficiency | ||||
| Inventory Turnover | 2.24 | 3.66 | 2.21 | 2.07 |
| Cash Conversion Cycle | 777.72 | -163.32 | -62.36 | -128.42 |